Staying asleep

Although the data will need to be confirmed in Phase III trials, Hypnion Inc. has disclosed Phase II results showing that HY10275 improved sleep maintenance, as measured by wake time after onset of sleep (WASO), more than that seen in marketed drugs Ambien CR zolpidem tartrate and Lunesta eszopiclone. In the double-blind, French trial in 52 patients, WASO decreased by 62 and 35 minutes for 3 and 1 mg HY10275 vs. placebo (p<0.001 and p<0.002, respectively).

HY10275 works via a dual mechanism as a selective histamine H1 and serotonin (5-HT2A) receptor modulator. According to President and CEO John Dee, the dual action appears to have synergistic effects...